Tenofovir use in a patient with a severe renal impairment.
Di Biagio
A
A
Department of Infectious Diseases, San Martino Hospital, University of Genoa, Genoa, Italy. antonio.dibiagio@hsanmartino.liguria.it
Bassetti
M
M
Briozzo
A
A
Ferrazin
A
A
Rosso
R
R
Gatti
G
G
Cruciani
M
M
Bassetti
D
D
D000225:Adenine / Q000009:adverse effects* / Q000031:analogs & derivatives*; D000328:Adult; D003928:Diabetic Nephropathies / Q000150:complications*; D015224:Dideoxynucleosides / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use; D063065:Organophosphonates / Q000009:adverse effects*; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects*; D000068698:Tenofovir; D016896:Treatment Outcome; D000099227:Abacavir
D000225:Adenine; D015224:Dideoxynucleosides; D019259:Lamivudine; D063065:Organophosphonates; D018894:Reverse Transcriptase Inhibitors; D000068698:Tenofovir; D000099227:Abacavir